Exploring International Legal Governance of Global Solar Fuels

This paper critically examines the role of international law in establishing the appropriate governance framework for enhanced global collaboration on solar fuels. It will particularly evaluate the right to enjoy the benefit of scientific progress and it

Trials and tribulations in the removal of dextropropoxyphene from the Australian register of therapeutic goods

The Therapeutic Goods Administration determined in November 2011 that dextropropoxyphene should be removed from the Australian Register of Therapeutic Goods. This is consistent with this drug's removal from the market in many other developed countries. H

ACT Human Rights Act: Legality of abortion remains with the Legislative Assembly

One current argument against the ACT Human Rights Bill, focuses on proposed provisions therein rendering it “unlawful” for public authorities to engage in conduct “incompatible” with “every human being’s inherent right to life” (clauses 2.1 and 6.1-2). These, it is alleged, may threaten the decriminalisation of abortion, recently achieved by legislation in this jurisdiction (Crimes (Abolition of Offence of Abortion) Act 2002)

Does the world need a global project on artificial photosynthesis?

This paper introduces a theme issue of Interface Focus derived from papers presented at the Royal Society supported meeting ‘Do we need a global project on artificial photosynthesis?’ held at Chicheley Hall in July 2014. At that meeting, leaders of national solar fuels and chemicals projects and research presented ‘state of the art’ on artificial photosynthesis (AP) in the context of the policy challenges for globalizing a practical technology to address climate change and energy and food security concerns. The discussions included contributions from many experts with legal and policy skills and uniquely focused on producing principles for prioritizing and specializing work while enhancing the funding and attendant public policy profile. To this end, representatives of major public, philanthropic and private potential stakeholders in such a project (such as the Wellcome Trust, the Moore Foundation, Shell, the Leighty Foundation, the EPSRC and Deutsche Alternative Asset Management) were invited to provide feedback at various points in the meeting. For this Interface Focus issue, speakers at the Chicheley Hall meeting were required to present a snapshot of their cutting edge research related to AP and then draw upon the Chicheley Hall discussions to innovatively analyse how their research could best be advanced by a global AP project. Such multidisciplinary policy analysis was not a skill many of these researchers were experienced or trained in. Nonetheless their efforts here represent one of the first published collections to attempt such a significant task. This introduction contains a brief summary of those papers, focusing particularly on their policy aspects. It then summarizes the core discussions that took place at the Chicheley Hall meeting and sets out some of the central ethical principles that were considered during those discussionsARC DP14010056

Towards a global solar fuels project - Artificial photosynthesis and the transition from anthropocene to sustainocene

The development of an economy based on practical solar fuels is chiefly predicated on obtaining cheap and abundant hydrogen by using photons to split water, then cooling or compressing that gas; or on combining such hydrogen with carbon dioxide obtained

Freedom of information applications as an "evergreening" tactic: Secretary, Department of Health and Ageing v iNOVA Pharmaceuticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA 1442

A recent decision of the Federal Court of Australia illustrates how patent-holding pharmaceutical companies are attempting to use Australia's Freedom of Information Act 1982 (Cth) to force Australian safety, quality and efficacy regulators to disclose whether generic competitors are attempting to enter the market. In Secretary, Department of Health and Ageing v iNova Pharmaceuticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA 1442 a single judge of the Federal Court overturned a decision of the Administrative Appeals Tribunal (AAT) that would have compelled the Australian Therapeutic Goods Administration (TGA) to reveal whether they were in possession of an application to register generic versions of two iNova products: imiquimod and phentermine. In its justification to the AAT for refusing to confirm or deny the existence of any application, the TGA argued that to reveal the existence of such a document would prejudice the proper administration of the National Health Act 1953 (Cth) as it could compromise the listing of a generic on the Pharmaceutical Benefits Scheme. The AAT failed to appreciate the extent to which this revelation to a competitor would have undercut 2004 amendments to the Therapeutic Goods Act 1989 (Cth) that provided penalties for evergreening tactics involving TGA notifications to drug patent-holders and 2006 amendments to the Patents Act 1990 (Cth) which protected the right of generic manufacturers to "springboard". The decision of the Federal Court is one of the first to explore the use of freedom of information legislation by patent-holders as a potential "evergreening" technique to prolong royalties by marginalising generic competition. Because of the significant amounts of money involved in ensuring rapid market entry of low-cost generic products, the issue has considerable public health significance

Implementing US-style anti-fraud laws in the Australian pharmaceutical and health care industries

This article critically analyses the prospects for introducing United States anti-fraud (or anti-false claims) laws in the Australian health care setting. Australian governments spend billions of dollars each year on medicines and health care. A recent report estimates that the money lost to corporate fraud in Australia is growing at an annual rate of 7%, but that only a third of the losses are currently being detected. In the US, qui tam provisions - the component of anti-fraud or anti-false claims laws involving payments to whistleblowers - have been particularly successful in providing critical evidence allowing public prosecutors to recover damages for fraud and false claims made by corporations in relation to federal and state health care programs. The US continues to strengthen such anti-fraud measures and to successfully apply them to a widening range of areas involving large public investment. Australia still suffers from the absence of any comprehensive scheme that not only allows treble damages recovery for fraud on the public purse, but crucially supports such actions by providing financial encouragement for whistleblowing corporate insiders to expose evidence of fraud. Potential areas of application could include direct and indirect government expenditure on health care service provision, pharmaceuticals, medical devices, defence, carbon emissions compensation and tobacco-related illness. The creation in Australia of an equivalent to US anti-false claims legislation should be a policy priority, particularly in a period of financial stringency